Get actionable findings from clinical measurements, cohorts, and trial data extracted from papers.
Press Enter β΅ to solve
Fuel Your Discoveries
"The important thing in science is not so much to obtain new facts as to discover new ways of thinking about them."
- William Lawrence Bragg
Quick Explanation
Copied
Everolimus vs CNI after liver transplant: renal outcomes (evidence available in provided sources)
Known from provided trials: very early everolimus with tacrolimus minimization increases early/longitudinal eGFR vs control (RCT), but increases wound/hernia and dyslipidemia risk ().
CNI-to-EVR conversion: PROTECT extension reports less renal deterioration over months 11β35 with EVR conversion vs continued CNI, with no clear worsening in mortality/rejection endpoints ().
Broader synthesis signal (but not computable here as a true meta-analysis): a systematic review of randomized trials reports renal benefits with everolimus plus reduced CNI, and higher adverse-event risk overall ().
Long Explanation
Meta-analysis request: Everolimus vs CNI after liver transplant renal outcomes
I canβt construct a true quantitative meta-analysis from the provided data because the inputs you supplied do not include per-study renal effect sizes (with variances) aggregated across multiple everolimusβCNI trials.
I can visualize the renal signal from the included randomized trial and conversion trial excerpts, and place it in context of the provided systematic review.
Evidence map (whatβs quantitatively visualized from provided sources)
De novo de novo liver transplant (POD7 EVR + TAC minimization): eGFR-MDRD4 differences over time; CKD distribution; dialysis and adverse events ().
Conversion at 4β8 weeks (CNI β EVR): renal deterioration comparison across months 11/23/35 using CockcroftβGault and Nankivell; plus mortality, rejection, and discontinuation ().
Systematic review (qualitative summary): renal benefit signal with EVR + reduced CNI; increased adverse events overall; EVR without CNI may increase acute rejection ().
Figure 1 β De novo EVR (POD7) vs TAC: renal trajectory (eGFR-MDRD4 median difference)
Interpretation: the excerpt reports larger eGFR-MDRD4 in the EVR arm at early and later timepoints (reported differences ~20β36 mL/min/1.73mΒ²) ().
Figure 2 β De novo EVR vs TAC: CKD distribution at 1 year
CKD category percentages are as reported in the trial excerpt ().
Caution: the provided dataset contains multiple CKD-related fields; exact mapping to the plotted values should be verified against the paper tables.
Figure 3 β De novo EVR vs TAC: dialysis-requiring acute renal failure (numerical)
Acute renal failure needing dialysis: EVR 4.3% vs control 10.6% (P=0.11) as reported in the excerpt ().
Figure 4 β Trade-off: EVR increased wound/hernia and dyslipidemia (de novo trial excerpt)
The excerpt reports higher rates of wound complications and incisional hernias with EVR, plus dyslipidemia ().
PROTECT extension: renal function deteriorated in CNI arm while remaining stable in EVR; reported group differences varied by formula and timing (e.g., CockcroftβGault at M11 p=0.240; Nankivell at M23 p=0.039; M35 p=0.015) ().
Figure 6 β Quality/limitations checklist (why a βmeta-analysisβ result might differ from simple trial excerpts)
Examples of limitations explicitly noted in the provided sources include: open-label design and dosing deviations in the de novo EVR trial (), and non-uniform renal measurement/possible publication bias in the systematic review ().
Bottom line (evidence-weighted, but not a computed pooled meta-analysis)
Renal function signal is directionally consistent in the provided randomized excerpts: very early EVR with tacrolimus minimization reports higher eGFR over time vs control ().
Conversion strategy also suggests reduced deterioration over months 11β35 vs continued CNI in PROTECT extension, with formula- and time-dependent statistical significance ().
Net benefit requires accounting for trade-offs: EVR initiation (in this early de novo setting) increased wound/hernia and dyslipidemia in the excerpt ().
Confidence (about a pooled, numeric meta-analytic estimate): low because the pooled-effect inputs required for a true meta-analysis are not present in the provided raw extraction; confidence (about directionality in the shown excerpts): moderate given randomized evidence and a consistent systematic-review qualitative signal ().
This agent can search within BGPTβs paper corpus to recover per-trial renal effect sizes (e.g., eGFR/CrCl changes) and then compute a true pooled meta-analysis with forest/funnel plots if the underlying full-text data are available.
It will pull renal endpoint values reported in full-text extracts for EVR vs CNI liver-transplant trials, then compute pooled effect sizes and heterogeneity for eGFR/CrCl across timepoints.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A simple claim that βeverolimus always preserves kidney function without increasing rejectionβ is weakened by the systematic reviewβs note that EVR without calcineurin inhibitors can increase acute rejection risk, and by the de novo trialβs trough-dependent rejection concerns (; ).
A strong prior that βrenal benefit should translate into clearly lower dialysis ratesβ is not supported in the excerpted RCT because dialysis-requiring ARF was numerically lower but not statistically significant (P=0.11) ().
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Fuel Your Discoveries
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Analysis 
Hypothesis Graveyard
Discussion